These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29974488)

  • 1. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
    Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
    Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
    Riglet F; Bertrand J; Barrail-Tran A; Verstuyft C; Michelon H; Benech H; Durrbach A; Furlan V; Barau C
    Drugs R D; 2020 Dec; 20(4):331-342. PubMed ID: 33025511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5'-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients.
    Thanukrishnan H; Venkataramanan R; Mehta RB; Jorgensen D; Sood P
    Clin Transplant; 2022 Dec; 36(12):e14830. PubMed ID: 36177865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.
    Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T
    Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
    Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
    Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Oellerich M; Shipkova M; Schütz E; Wieland E; Weber L; Tönshoff B; Armstrong VW
    Ther Drug Monit; 2000 Feb; 22(1):20-6. PubMed ID: 10688252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
    Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
    J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].
    Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M
    Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
    Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
    Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.
    Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P
    Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
    Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.